Back to top

Image: Bigstock

Here's Why You Should Add PRA Health to Your Portfolio Now

Read MoreHide Full Article

PRA Health Sciences, Inc. (PRAH - Free Report) is well poised for growth on the back of strong international expansion, improving Contact Research Organization (CRO) industry and favorable biopharmaceutical industry dynamics.

The stock currently carries a Zacks Rank #2 (Buy).

Price Performance

Shares of PRA Health Sciences have gained 5.2%, against the industry’s decline of 16.9% on a year-to-date basis. Meanwhile, the S&P 500 Index rallied of 18.1% in the same timeframe.



Factors to Boost PRA Health

The CRO industry has been gaining traction of late on the back of worldwide increase in demand for outsourced clinical development solutions. Going by a CRO Market Size Projections report by Industry Standard Research (ISR), the size of the worldwide CRO market was approximately $32 billion in 2016 and is anticipated to hit $44 billion in 2021 at a CAGR of 7%.

International expansion has been and continues to be a major growth driver. This is because PRA Health is one of the largest CROs globally on the basis of revenues, focusing on executing clinical trials on a worldwide basis.

We note that, PRA Health’s revenues from international operations is growing fast (currently Europe, Africa, and Asia-Pacific region contributes more than 30% to total revenues).
The company continues to gain from large pharmaceutical companies, which contributed to the top line in recent times.

Moreover, a solid 2019 outlook instills optimism in the stock. For 2019, PRA Health anticipates to achieve total revenues between $3.02 billion and $3.10 billion, representing reported growth of 5-8% and 6-8% at constant currency.

Adjusted EPS for 2019 is expected between $4.98 and $5.08, indicating growth of 16% to 19% from 2018.

Which Way Are Estimates Headed?

For 2019, the Zacks Consensus Estimate for revenues is pegged at $3.06 billion, indicating an improvement of 9.3% from the year-ago period. For adjusted earnings per share, the same is pinned at $5.07, suggesting growth of 18.5% year-ago reported figure.

Other Stocks to Consider

Some other top-ranked stocks from the broader medical space are Nissan Chemical Corporation (NNCHY - Free Report) , Straumann Holding AG (SAUHF - Free Report) and McKesson Corporation (MCK - Free Report) , each currently carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank  (Strong Buy) stocks here.

Nissan Chemical has a long-term earnings growth rate of 10%.

Straumann Holding has a long-term earnings growth rate of 18%.

McKesson has a long-term earnings growth rate of 6.9%.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.50% per year. So be sure to give these hand-picked 7 your immediate attention.

See them now >>